DocWire News spoke with Parameswaran Hari, MD, Chief of Hematology/Oncology at the Medical College of Wisconsin, on clinical considerations for selecting chimeric antigen receptor (CAR) T cell therapy for multiple myeloma, and anticipated financial challenges patients may face as this option grows in availability.
This is the final installment of a three-part conversation with Dr. Hari. Watch part one, where Dr. Hari reviews some highlights in multiple myeloma from the ASH annual conference, and part two, where he discusses the benefits of autologous transplantation for this disease.